ICOTF Stock UPDATES Ico Therapeutics (ICOTF) 0.0540 08/03/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ico Therapeutics (ICOTF) 0.0540 $ICOTF

iCo Therapeutics Inc. - No Material Change
CNW Group - Tue Jul 15, 12:29PM CDT
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), at the request of IIROC, confirms that there is no material change that would account for the recent increase in market activity.

Immune Appoints Cameron Durrant, MD, MBA to Board of Directors
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company" appointed Dr. Cameron Durrant as new independent director. Dr. Durant becomes a Member of the Compensation Committee and the R&D Committee.

iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders
PR Newswire - Mon Jun 30, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) today announced that all nominees listed in the management information circular datedMay 28, 2014were elected as directors at its 2014 Annual Meeting of Shareholders, held onFriday, June 27, 2014. On a vote by ballot, the following five nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows:

iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema
CNW Group - Mon Jun 09, 7:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) today announced top-line results related to the eight month visual acuity (VA) primary endpoint for subjects enrolled in the Phase 2 iDEAL Study, conducted in collaboration with JDRF, evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME).

Immune Appoints Gad Berdugo to Board of Directors and Karin Hehenberger, M.D., Ph.D to Senior Vice President
GlobeNewswire - Fri Jun 06, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company" appointed Mr. Gad Berdugo as new independent director and Karin Hehenberger, M.D., Ph.D., as Senior Vice President, Medical Affairs and Corporate Communications.

iCo Therapeutics Announces First Quarter 2014 Financial Results
PR Newswire - Thu May 29, 4:00PM CDT
iCo Therapeutics ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended March 31, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS" .

Immune Pharmaceuticals Announces First Quarter 2014 Financial Results
GlobeNewswire - Wed May 21, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) and (Nasdaq:IMNP) ("Immune" or "the Company" announced today its financial results for the three month period ended March 31, 2014.

Immune CEO Announces New Operational Leadership Team
GlobeNewswire - Wed Apr 02, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today the addition of two new senior members to its management team.

Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.

iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study
CNW Group - Wed Mar 05, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2 investigator-sponsored study is evaluating the efficacy and safety of iCo-007 after repeated injections in patients with Diabetic Macular Edema (DME). The study's primary endpoint is change in visual acuity from baseline to month eight, followed by secondary endpoints at month twelve. Next steps include data queries and subsequent data lock. Once these activities are complete, the results will be analyzed and top-line results will be made public.

iCo Therapeutics Announces DTC Approval
PR Newswire - Tue Feb 25, 12:15PM CST
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) today announced that its United States trading symbol ICOTF has received approval from The Depository Trust Company (the "DTC" , thus providing the Company with DTC eligibility.

IIROC Trade Resumption / L'OCRCVM permet la reprise de la négociation - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 9:20AM CST
Trading resumes in / Reprise des negociations pour:

iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing
PR Newswire - Mon Jan 27, 9:03AM CST
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) announced today that it has closed its previously announced overnight marketed offering of equity securities (the "Offering" . Pursuant to the Offering, iCo issued 16,206,483 units of the Company ("Units" at a price of $0.4165 per Unit for aggregate gross proceeds of C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share" and three-quarters of one common share purchase warrant (each whole warrant, a "Warrant" . Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one Common Share for a period of five years following the date of issuance of the Warrant.

IIROC Trading Halt / Suspension de la négociation par l'OCRCVM - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 8:43AM CST
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :

iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing
PR Newswire - Wed Jan 22, 7:42AM CST
iCo Therapeutics Inc. ("iCo" or the "Company" (TSX-V: ICO) (OTCQX: ICOTF) is pleased to announce today that the Company has priced its previously announced overnight marketed offering of equity securities (the "Offering" . Pursuant to the Offering, iCo will issue an aggregate of up to 16,206,483 units of the Company ("Units" at a price of C$0.4165 per Unit for aggregate gross proceeds of approximately C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share" and three-quarter of one common share purchase warrant (each whole warrant, a "Warrant" . Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one common share of the Company (a "Warrant Share" for a period of five years following the closing of the Offering.



Scroll down for more posts ▼

Top 10 Most Recent News Articles

Circuit Adds Gabe Klein as Microtransit Expansion Adviser

Updated Category News Views 29

Municipal mobility is a slow, political grind, not a shiny-app contest, and Circuit’s decision to add Gabe Klein to its board looks aimed squarely at that reality. The all-electric microtransit operator has brought aboard somebody who has worked inside the machinery of city government, federal transportation policy, electrification, venture investing, and transportation...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 256

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 5

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 14

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 129

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 91

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 51

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 157

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 265

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 134

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading

Top 5 Most Recently Viewed Articles

Jøtul Group's Financial Challenges and Strategic Response

Updated Category News Views 138

Understanding the Jøtul Group's Financial Landscape The Jøtul Group is a major player in the fireplace market, known for its exceptional range of products that cater to various consumer preferences. Founded in 1853, this company proudly represents some of Europe's most reputable brands, including Jøtul, Scan, and Ravelli. Each brand encapsulates a unique design...

Continue Reading
Capri Holdings Limited Faces Legal Scrutiny: What You Need to Know

Updated Category News Views 425

Capri Holdings Limited Under Investigation Capri Holdings Limited, known for its involvement in the luxury fashion sector, has recently come under the spotlight due to an ongoing investigation. This investigation is being led by the Law Offices of Howard G. Smith on behalf of the investors of the company. The core of the inquiry centers around potential violations of...

Continue Reading
eBay's Year-End Performance and 2025 Outlook Highlights

Updated Category News Views 1606

eBay Inc. Financial Performance Overview eBay Inc. has showcased remarkable financial growth in its latest performance report. The company announced substantial revenue figures and gross merchandise volume (GMV) for the last quarter and the full year, reinforcing its position as a leading global commerce platform. Key Financial Highlights of Q4 eBay's revenue reached an...

Continue Reading
Join Us for a Free Webinar on Stepfamily Support Strategies

Updated Category News Views 183

Understanding Stepfamily Dynamics Navigating the complexities of blended families can be challenging, and that is exactly why this free webinar, titled From Conflict to Connection: Navigating Stepfamily Dynamics, offers unparalleled insights for parents and stepparents alike. The event is set to feature expert panelists who specialize in co-parenting and stepfamily...

Continue Reading
Lamb Weston Faces Sharp Decline Amid Nasdaq Rally in Stocks

Updated Category News Views 143

Nasdaq Composite Shows Robust Gains The U.S. stock market experienced a positive trajectory as the Nasdaq Composite surged over 1% on a recent trading day. Investors found motivation in the optimistic outlook surrounding technology shares, which rose by 1.6%. Dow and S&P 500 Performance The Dow Jones Industrial Average reflected a modest uptick of 0.55%, reaching an...

Continue Reading